The Bitter Pill: Why Australians Are Missing Out on Life-Changing Medicines
There’s a quiet crisis brewing in Australia’s healthcare system, one that doesn’t make headlines as often as it should. It’s not about hospital wait times or doctor shortages—it’s about the medicines Australians can’t access. Eighteen, to be precise. Eighteen life-changing treatments for conditions like cancer, schizophrenia, and rare diseases that are available elsewhere but remain out of reach here. What’s striking isn’t just the number; it’s the human cost. Take Tina Powney, for example, a woman from Shepparton who’s been living with idiopathic pulmonary arterial hypertension (IPAH) for 26 years. Her daily routine is a logistical nightmare, involving IV infusions, backup pumps, and a bedroom filled with medication. A new drug, Sotatercept, could simplify her life to a single injection every three weeks. But at $16,000 out-of-pocket, it’s a luxury she can’t afford.
What makes this particularly fascinating is how Australia, once a leader in healthcare innovation, has become a laggard. The Pharmaceutical Benefits Scheme (PBS), designed to make medicines affordable, is now a bottleneck. Only a quarter of new global medicines launched in the last decade have been subsidized here. Personally, I think this isn’t just a policy failure—it’s a moral one. Patients like Tina are paying the price for a system that prioritizes cost-cutting over innovation.
One thing that immediately stands out is the complexity of Australia’s drug approval process. The government negotiates lower prices by buying in bulk, which sounds great on paper. But the catch? New medicines must prove they’re significantly better than cheaper alternatives. This creates a Catch-22: innovative treatments struggle to compete with older, dirt-cheap drugs, even if they’re more effective or easier to use. If you take a step back and think about it, this system disincentivizes progress. Why would pharmaceutical companies invest in Australia when their cutting-edge products are treated the same as decades-old generics?
From my perspective, the real issue isn’t just the process—it’s the mindset. Australia’s approach to healthcare funding feels stuck in the past. Since 2015-16, investment in innovative medicines has dropped from 6.2% to 4.1% of the health budget. Meanwhile, the likelihood of a new medicine being reimbursed within two years of U.S. approval has halved. This raises a deeper question: Are we willing to sacrifice innovation for short-term savings?
A detail that I find especially interesting is the global context. The Trump administration’s “most favoured nation” policy is pushing drug prices down in the U.S., but at what cost? Pharmaceutical companies are now wary of launching products in smaller markets like Australia, fearing it could set a lower global price baseline. What this really suggests is that Australia’s problem isn’t just internal—it’s part of a larger global shift in pharmaceutical economics.
In my opinion, the solution isn’t just about speeding up approvals or increasing funding. It’s about rethinking how we value innovation. The Health Technology Assessment (HTA) review commissioned in 2022 offered 50 recommendations to streamline the process, but implementation has been slow. Health Minister Mark Butler’s acknowledgment of the issue is a start, but patients like Tina can’t afford to wait.
What many people don’t realize is how this issue affects everyday Australians. A McKell Institute survey found that 43% of Australians have been prescribed a medicine not on the PBS, and 29% have paid out-of-pocket for non-listed drugs in the last three years. This isn’t a niche problem—it’s widespread. And yet, public awareness remains low. If more people understood the scale of this issue, I believe there would be a louder call for change.
Personally, I think the most frustrating part is the missed potential. Australia has the resources and the expertise to be a leader in healthcare again. But without a shift in priorities, we’ll continue to fall behind. The 18 missing medicines are just the tip of the iceberg. What this really suggests is that the system isn’t broken—it’s outdated.
If you take a step back and think about it, this isn’t just about drugs or budgets. It’s about quality of life. It’s about whether we’re willing to invest in a future where diseases like schizophrenia, prostate cancer, and rare conditions are no longer life sentences. The question isn’t whether we can afford to change the system—it’s whether we can afford not to.
In the end, the story of Australia’s missing medicines is a cautionary tale. It’s a reminder that progress isn’t automatic—it requires vision, investment, and a willingness to adapt. For patients like Tina Powney, the stakes couldn’t be higher. The question is: Will we act before it’s too late?
